Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–1 of 1 results
Advanced filters: Author: Kanthi Kollengode Clear advanced filters

  • In the phase 1/2 TRIDENT-1 trial, treatment of patients with NTRK fusion–positive advanced solid tumors with the tyrosine kinase inhibitor repotrectinib—selective for ROS1, TRKA−C and ALK—was safe and resulted in durable systemic and intracranial clinical response.

    • Benjamin Besse
    • Jessica J. Lin
    • Benjamin J. Solomon
    ResearchOpen Access
    Nature Medicine
    P: 1-8